STOCK TITAN

Q BioMed Inc - QBIO STOCK NEWS

Welcome to our dedicated news page for Q BioMed (Ticker: QBIO), a resource for investors and traders seeking the latest updates and insights on Q BioMed.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Q BioMed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Q BioMed's position in the market.

Rhea-AI Summary
Q BioMed provides an update to shareholders regarding their financials and OTC listing status. The company was unable to file complete audited financials for 2022 and has been downgraded to the 'Expert Market'. They are working to find a solution for funding and relisting or possible M&A.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
133.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
188%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.41%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.61%
Tags
none
Q BioMed Inc

OTC:QBIO

QBIO Rankings

QBIO Stock Data

14.51k
140.88M
2.99%
Custom Computer Programming Services
Professional, Scientific, and Technical Services
Link
United States
New York

About QBIO

q biomed inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. the company offers strontium chloride sr89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. it is also developing man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; qbm-001 for rare pediatric non-verbal autism spectrum disorder; and uttroside-b for liver cancer. q biomed inc. has a partnership with mannin research for the development of novel covid-19 therapeutics. the company was formerly known as ismo tech solutions, inc. and changed its name to q biomed inc. in july 2015. q biomed inc. was founded in 2013 and is based in new york, new york.